Quick Facts: Uses and Benefits

• Chronic Venous Disease (CVD): May provide relief from common symptoms like pain, heaviness, cramps, and swelling (edema).
• Venous Ulcers: May support the healing process of venous leg ulcers.
• Thrombotic Risk: Used for the prophylaxis and management of vascular diseases associated with an elevated risk of blood clots (thrombosis).

---

Vessel Due F, which contains the active ingredient sulodexide, is a prescribed medication used to manage and support conditions related to the vascular system. Its primary role is in the therapeutic domain of blood vessel disorders where an increased risk of blood clot formation is a concern. The medication is utilized in the management of both arterial and venous peripheral vascular diseases.

For patients with Chronic Venous Disease (CVD), the drug may provide relief from a variety of uncomfortable symptoms, including leg pain, the sensation of heaviness, night cramps, and localized swelling (edema). Furthermore, it is incorporated into treatment plans to help accelerate the healing of chronic venous ulcers, which may contribute to a better overall quality of life.

The medication is also relevant in the prevention of recurrent venous thromboembolism in certain patient populations after initial anticoagulant therapy has concluded. The use of this drug for specific indications is utilized across various therapeutic applications.

The eligibility profile for Vessel Due F (sulodexide) is strictly defined by official regulatory documents, focusing primarily on absolute prohibitions and populations with insufficient safety data. Use is generally established for adult patients with approved vascular conditions.

Who Must Not Use Vessel Due F (Contraindications)

Use of this medicine is contraindicated and explicitly prohibited in patients with a known hypersensitivity to sulodexide, heparin, or other similar glycosaminoglycans. It must also not be used by any patient with an existing active bleeding disorder, hemorrhagic diathesis, or any pathological condition that is associated with a high risk of hemorrhage.

Restricted and Non-Established Use

• Pregnancy and Lactation: Use is not recommended. Official labeling states that safety and efficacy have not been established in pregnant or breastfeeding individuals due to a lack of clinical data.
• Pediatric Patients: Safety and efficacy have not been established for use in children and adolescents, and the drug is not approved for routine use in this age group.
• Organ Impairment: Caution is required for use in patients with known renal impairment or hepatic impairment as these conditions may affect the body’s ability to process and eliminate the drug.

Eligibility Classification

This eligibility profile establishes absolute non-eligibility based on hemorrhage risk or allergy (contraindicated) and mandates restricted use or non-recommendation for populations where safety is uncertain (e.g., pediatric, pregnant, or lactating individuals), as defined by regulatory documents.

Interaction Map: Interactions with other medicines and products — Official Regulatory Information for Vessel Due F

---

Interaction Scope

Medicinal product categories with documented interactions	Oral Anticoagulants, Antiplatelet Agents, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Fibrinolytic/Thrombolytic Agents, Aminoglycoside Antibiotics.
Specific interacting medicines (if explicitly listed)	Warfarin, Acetylsalicylic acid, Apixaban.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic potentiation (additive effect on blood coagulation/hemostasis).
Timing-based interaction rules (if applicable)	None documented in official regulatory sources.
Population-specific interaction notes (if applicable)	None documented specifically detailing enhanced interaction risk in specific populations.
Interaction-related restrictions	Strict caution is required against co-administration with products that affect blood coagulation and hemostasis due to the documented risk of bleeding/hemorrhage.

---

Interaction Classifications (High-Level)

Interaction severity classification	Risk of Combined Hemorrhagic Effect; Decreased Therapeutic Efficacy.
Regulatory basis	Public regulatory monographs and pharmacology summaries.
Interaction-context constraints	The constraint is the additive pharmacodynamic effect on blood clotting factors.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with oral anticoagulants carries a documented risk of increased bleeding and hemorrhage.
• Co-administration with antiplatelet agents (e.g., acetylsalicylic acid) and NSAIDs is formally associated with an increased risk of bleeding.
• The therapeutic activity of aminoglycoside antibiotics may be reduced when co-administered with this medicine.
• The medicine carries a risk of combined hyperkalemia when used with certain medicinal products known to elevate potassium levels.

Connection to the overall interaction profile:

Official regulatory documents define the interaction structure of sulodexide primarily around a significant pharmacodynamic potentiation of other medicines that interfere with blood coagulation, which necessitates regulatory caution due to the formal risk of hemorrhage. The profile is further defined by the absence of officially documented restrictions based on metabolic pathways, specific drug transporters, food, alcohol, or mandatory timing separation.

Vessel Due F (Sulodexide) exerts its action through a multi-faceted pharmacodynamic mechanism, primarily by targeting the anticoagulation system and the integrity of the vascular wall. Its effects result in modulation of the blood clotting cascade and influence on vascular integrity.

Augmenting Natural Anticoagulation

Its mechanism involves enhancing the inhibitory activity of endogenous anticoagulant proteins, specifically Antithrombin III (ATIII) and Heparin Cofactor II (HCII), against activated clotting factors such as Factor Xa and Thrombin. This targeted potentiation contributes to limiting the formation of fibrin, leading to a predictable physiological adjustment within the coagulation pathway.

Modulating Vascular Endothelial Integrity

The drug influences the physical integrity and function of the blood vessel lining (the endothelium). It modulates the molecular components of the endothelial glycocalyx and promotes the release of Nitric Oxide (NO). These actions influence signaling dynamics within the vascular tissue, leading to physiological consequences that modulate vascular tone and reduce cellular adhesion to the vessel wall.

Influencing Hemorheology

This domain focuses on the composition and flow properties of the blood. The drug engages mechanisms that influence lipoprotein lipase (LPL) activity, thereby assisting in the clearance of circulating triglycerides. This modification of plasma factors may contribute to lowering plasma viscosity, thereby influencing hemorheological properties.

How to Use Vessel Due F

Vessel Due F, which contains the active substance sulodexide, is administered according to a two-part sequential regimen defined by official prescribing information. This approach transitions the patient from an initial, higher-strength dose administered by injection to a long-term, lower-strength dose administered orally.

---

Official Administration Protocol

Instruction Component	Official Guideline (Based on Regulatory Posology)
Route of Administration	Treatment begins with a parenteral route (Intramuscular (IM) or Intravenous (IV)), which is followed by an Oral phase for maintenance.
Standard Dosing Schedule	The regimen typically starts with a daily dose of 600 LSU (Lipasemic Units) in the injectable form, then transitions to 250 LSU taken twice daily in the oral capsule form.
Frequency Pattern	The injectable dose is administered once daily; the oral maintenance dose is administered twice daily (BID).
Initial Course Duration	The initial injectable course is typically administered for a period of 15 to 20 days before switching to the oral form.
Maintenance Course Duration	The oral phase can continue for an initial 30 to 40 days, and for specific indications, such as the prevention of recurrent venous thromboembolism, use may be documented for up to two years.

---

Procedural Structure

The usage protocol is based on a structured transition. The initial administration via IM or IV injection usually requires a clinical or supervised setting. Following this acute phase, the patient transitions to the patient-managed oral therapy. The official prescribing information does not uniformly detail specific numerical dose adjustments for populations like older adults or those with renal or hepatic impairment, nor does it provide explicit instructions on handling a missed dose in high-level summaries.

Recent Clinical Evidence Overview

Clinical trials involving the active substance in Vessel Due F (sulodexide) have primarily focused on its use in Chronic Venous Disease (CVD), which includes conditions like chronic venous insufficiency, and the secondary prevention of Venous Thromboembolism (VTE).

---

Chronic Venous Disease

Studies have investigated the effects of sulodexide on the signs and symptoms of CVD, a condition characterized by venous hypertension and inflammation.

Research has explored whether treatment is associated with a reduction in major CVD symptoms, such as pain, cramping, and leg heaviness. Results from several clinical trials suggest that administration was associated with a decrease in the intensity of these symptoms in patients with various stages of CVD, including those with venous ulcers (CEAP class C6).

---

Venous Thromboembolism Prevention

Randomized, double-blind trials have specifically studied the role of sulodexide in patients who have completed initial anticoagulant therapy for unprovoked VTE (Deep Vein Thrombosis or Pulmonary Embolism).

The evidence has been analyzed to determine if the continuous use of oral sulodexide after the initial anticoagulant course may be associated with a reduced rate of VTE recurrence over a period of 1 to 2 years, particularly in elderly patients. This is an important area of research, as it explores alternative strategies for long-term secondary prevention.

---

Safety Profile in Research

In major clinical trials, the rate of reported adverse events (AEs) was found to be comparable between the sulodexide and placebo groups. The overall risk of AEs, including bleeding episodes (which are a concern with medications affecting clotting), was observed to be low in the studies.

Common questions about Vessel Due F (FAQ)

Q: What should I do if I forget to take a dose of the oral capsule?

Official guidance indicates that if a dose is missed, it can be taken when remembered. However, if the time for the next scheduled dose is near, the official guidance suggests skipping the missed dose instead. Official patient information also advises not to take two doses at the same time to compensate for a dose that was forgotten.

Q: Does Vessel Due F interact with food or alcohol?

Official product information notes caution regarding alcohol and often advises against its consumption while taking this medicine. When it comes to food, the regulatory documents primarily focus on interactions with other medicines, and specific restrictions regarding food consumption are typically not stated.

How to Store and Dispose of Vessel Due F

The storage and disposal of Vessel Due F (sulodexide) must adhere strictly to the conditions mandated by official regulatory labeling to maintain stability and prevent environmental harm.

---

Official Storage Requirements

The medication must be stored at a temperature no higher than 30°C and should be protected from excessive heat. It is mandatory to keep Vessel Due F out of the sight and reach of children. The product must not be used after the expiration date printed on the packaging, and any product with damaged packaging should not be used.

---

Official Disposal Instructions

To protect the environment, unused or expired Vessel Due F must not be disposed of via wastewater or household waste. Patients should consult a pharmacist or local waste management service for the proper methods to dispose of the medicine in accordance with local requirements.